These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 24070136

  • 1. Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?
    Kaynar L, Metan G, Gökahmetoğlu S, Kurnaz F, Mumcuoğlu H, Öztürk A, Şıvgın S, Pala C, Yıldız O, Eser B, Ünal A, Çetin M.
    J Chemother; 2013 Oct; 25(5):286-91. PubMed ID: 24070136
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oral Valganciclovir as Preemptive Therapy for Cytomegalovirus Reactivation in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Atay D, Erbey F, Akcay A, Dag A, Ozturk G.
    J Pediatr Hematol Oncol; 2015 Oct; 37(7):543-7. PubMed ID: 26207778
    [Abstract] [Full Text] [Related]

  • 5. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ, Al Mohareb F, Al Rabiah F, Chaudhri N, Al Sharif F, Al Zahrani H, Mohamed SY, Patel M, Rasheed W, Nurgat Z, Bakr M, Ahmed S, Zaidi S, Nasser A, Ibrahim K, Al Abdely H, Aljurf M.
    Hematol Oncol Stem Cell Ther; 2010 Oct; 3(3):116-20. PubMed ID: 20890068
    [Abstract] [Full Text] [Related]

  • 6. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M.
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [Abstract] [Full Text] [Related]

  • 7. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY, Kang HJ, Hong CR, Lee JW, Kim H, Park KD, Shin HY, Park JD, Choi EH, Lee HJ, Ahn HS.
    Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
    [Abstract] [Full Text] [Related]

  • 8. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF.
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [Abstract] [Full Text] [Related]

  • 9. Preemptive therapy for cytomegalovirus disease in allogeneic stem cell transplant recipients.
    de la Cruz-Vicente F, Cerezuela Martinez P, Gil-Espárraga E, Martin Aguilera C, Aguilar Guisado M, Parody Ruiz-Berdejo R, Cisneros Herreros JM, Urbano-Ispizua A, Espigado Tocino I.
    Transplant Proc; 2008 Nov; 40(9):3102-3. PubMed ID: 19010207
    [Abstract] [Full Text] [Related]

  • 10. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
    Liu KY, Wang Y, Han MZ, Huang H, Chen H, Liu QF, Wang JM, Liu T, Song YP, Ma J, Wu DP, Zou P, Huang XJ.
    Chin Med J (Engl); 2010 Aug; 123(16):2199-205. PubMed ID: 20819665
    [Abstract] [Full Text] [Related]

  • 11. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, Harada N, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T, for Fukuoka Blood and Marrow Transplant Group (FBMTG).
    Int J Hematol; 2009 Mar; 89(2):231-237. PubMed ID: 19148587
    [Abstract] [Full Text] [Related]

  • 12. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM, Kwon CH, Joh JW, Ha YE, Sinn DH, Choi GS, Peck KR, Lee SK.
    PLoS One; 2015 Mar; 10(5):e0123554. PubMed ID: 25942443
    [Abstract] [Full Text] [Related]

  • 13. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC.
    Antivir Ther; 2005 Jan 15; 10(1):119-23. PubMed ID: 15751769
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 15; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial.
    Togashi J, Sugawara Y, Hashimoto M, Tamura S, Kaneko J, Aoki T, Hasegawa K, Kokudo N.
    Biosci Trends; 2011 Jan 15; 5(5):217-22. PubMed ID: 22101378
    [Abstract] [Full Text] [Related]

  • 20. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I, Len O, de la Cámara R, Gurguí M, Martino R, Jarque I, Barrenetxea C, Díaz de Heredia C, Batlle M, Rovira M, de la Torre J, Torres A, Aguilar M, Espigado I, Martín-Dávila P, Bou G, Borrell N, Aguado JM, Pahissa A, Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain.
    Antivir Ther; 2011 Jan 15; 16(7):951-7. PubMed ID: 22024510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.